Patent Application
20220314021
The present invention relates to photodynamic therapy using 5-aminolevulinic acids.
Photodynamic therapy (PDT) is therapy that utilizes the killing effect of reactive oxygen species including singlet oxygen generated by excitation by administering a photosensitizer or its precursor, causing the photosensitizer to accumulate in affected areas such as tumor tissues, newborn blood vessels, and skin surfaces, and irradiating a light beam corresponding to an absorption band wavelength of the photosensitizer as excitation light.
5-aminolevulinic acids (5-ALA) are oral absorbability and metabolized to protoporphyrin IX (PpIX) in the process of biosynthesis of heme in intracellular mitochondria. PpIX is a photosensitizer that has an absorption band near 410 nm, called a Soret band, and an absorption band near 500 to 650 nm, called a Q band, and generates reactive oxygen species by irradiation with light having these absorption band wavelengths, and is used for PDT.
Regarding PDT using 5-ALAs, Patent Document 1 describes that the intracellular accumulation of PpIX biosynthesized from 5-ALA increased in a 5-ALA concentration-dependent manner, and the sensitivity of the cells to light irradiation increased, that is, the cells were likely to die. In addition to the intracellular PpIX accumulation, it is also known in the art that the effect of PDT depends on light irradiation energy density, which is an integrated value of the light illuminance and the irradiation time (Patent Document 2).
As described above, while it is known that there is a tendency to depend on these factors, an exact relationship between the intracellular PpIX accumulation and the light irradiation energy density toward the killing effect in PDT has not been clarified so far. In addition, any relationship or similarity between these dependencies on the killing effect in different target cell types, origins, and primary diseases is not known beyond the types and origins of the target cell and the like.
In addition, Patent Documents 3 and 4, and Non-Patent Document 1 relate to PDT, but fail to disclose any strict relationship between the intracellular PpIX accumulation and the light irradiation energy density toward the killing effect in PDT.
In PDT, excessive light irradiation kills normal cells and leads to increased side effects, while under-irradiation cannot sufficiently kill target cells.
It is an object of the present invention to provide a method for determining condition parameters for optimized photodynamic therapy by accurately determining the condition parameters of photodynamic therapy.
It is also an object of the present invention to provide a photodynamic therapy apparatus using such a method for determining condition parameters for photodynamic therapy.
In the present invention, it has been found that cell death is curvilinearly regressed by a certain regression curve, for example, a four-parameter logistic model, depending on the intracellular PpIX accumulation and the light irradiation energy density regardless of cell species. Thus, it is possible to determine a proper amount of light irradiation energy and a dose of photosensitizer, and to predict a therapeutic effect, in a target disease where PpIX accumulation is observed.
Thus, the present invention provides a method for determining condition parameters for photodynamic therapy in which after administration of 5-aminolevulinic acids, protoporphyrin IX accumulated in cells is irradiated with light, the method including steps of:
calculating, by a processor in an experimental phase, a regression curve representing a correlation among three condition parameters: cell viability (Y), intracellular protoporphyrin IX accumulation (X), and light irradiation energy density (P); and
selecting in advance, by the processor prior to initiation of therapy, two condition parameters from the cell viability (Y), the intracellular protoporphyrin IX accumulation (X), and the light irradiation energy density (P), and then determining the remaining condition parameter using the regression curve.
Further, a photodynamic therapy apparatus according to the present invention includes:
It is preferable that the regression curve is expressed by the following model equation using four parameters A to D.
Y=(A−D)/(1+(X/C){circumflex over ( )}B)+D
It is preferable that the cell has a protoporphyrin IX-accumulating disease selected from a group consisting of leukemia, tumor, cancer, viral infection, skin disease, eye disease, autoimmune disease, and graft-versus-host disease (GVHD).
The present invention also relates to a photodynamic therapy composition including 5-aminolevulinic acids having a dose corresponding to the intracellular protoporphyrin IX accumulation (X) determined by the above-described method for determining condition parameters for photodynamic therapy.
The present invention also provides a method for determining light irradiation conditions in photodynamic therapy in which a subject is light-irradiated to inactivate cells with protoporphyrin IX accumulation after administration of 5-aminolevulinic acids to the subject, the method including steps of:
measuring, by a processor, an accumulation of protoporphyrin IX in cells from the subject; and
determining, by the processor, light irradiation energy density using a predetermined relational expression based on the accumulation of protoporphyrin IX measured in the above step.
It is preferable that said relational expression is determined based on a regression curve representing a correlation among the three condition parameters of cell viability (Y), intracellular protoporphyrin IX accumulation (X), and light irradiation energy density (P), which are calculated in advance.
It is preferable that said relational expression includes a lookup table illustrating a relationship among the protoporphyrin IX accumulation (X) and the light irradiation energy density (P).
It is preferable to determine a plurality of times of light irradiation when the measured protoporphyrin IX accumulation is less than a predetermined value.
The method for determining the condition parameters for photodynamic therapy according to the present invention also preferably includes steps of:
measuring, by a processor, cell viability of a subject after performing therapy using condition parameters determined using said regression curve, and estimating an intracellular protoporphyrin IX accumulation based on the obtained cell viability; and
resetting, by the processor prior to initiation of the next therapy, the light irradiation energy density and the 5-aminolevulinic acid dose using the estimated intracellular protoporphyrin IX accumulation.
In the present invention, the 5-aminolevulinic acids (5-ALAs) include 5-aminolevulinic acid (5-ALA) or a derivative thereof, or a salt thereof. Various administration forms such as intravenous injection, drip infusion, oral administration, transdermal administration, suppository, and intravesical injection can be adopted for administration of such 5-aminolevulinic acids.
A problem in photodynamic therapy is that excessive light irradiation kills normal cells and leads to increased side effects, while under-irradiation cannot sufficiently kill target cells. Therefore, by adapting the results of regression analysis according to the present invention, light irradiation energy density or a dose of the photosensitizer that appropriately induces cell death can be determined from an intracellular protoporphyrin IX accumulation in target cells of the disease to be treated (leukemia or the like).
In addition, upon calculating an effective protoporphyrin IX accumulation from a correlation between the protoporphyrin IX accumulation and a killing effect, a cancer cell population out of the effective range of protoporphyrin IX accumulation can be calculated to estimate an amount of irradiation, irradiation times, and the like for finally achieving a clinical effect.
The light source 20 has a function of irradiating protoporphyrin IX (PpIX) accumulated in cells with light after administering 5-aminolevulinic acids (5-ALAs) to a subject. The wavelength of light is set to an absorption wavelength of PpIX, for example, 410 nm, 545 nm, 580 nm, and 630 nm. The light intensity control unit 21 controls light irradiation energy density (P) of the light emitted from the light source 20.
The processor 10 performs control of the entire apparatus, data processing, and the like according to a preset program. The data input unit 11 includes a manual input device, such as a keyboard, a touch panel, and a mouse, or a remote input device by wired communication or wireless communication. The data storage unit 12 includes a semiconductor memory, a hard disk, and an optical disk. The data output unit 13 includes a display and a printer.
Next, in step s2, cells having various amounts of PpIX accumulation are irradiated with light at various light irradiation energy densities (joules per unit area), and viabilities of individual cells are measured. The various light irradiation energy densities used and the measured viabilities of the individual cells are input through the data input unit 11 and stored in the data storage unit 12. Next, the processor 10 performs regression analysis and fitting on the three condition parameters of cell viability (Y), intracellular PpIX accumulation (X), and light irradiation energy density (P) which are stored in the data storage unit 12 according to predetermined statistical analysis software to calculate a regression curve representing a correlation among the condition parameters. Any model equation can be assumed for the regression curve, but it is preferable to express the regression curve by the following model equation (1) using four parameters A to D. The calculated regression curve and the parameters A to D defining the regression curve can be stored in the data storage unit 12 and displayed on the data output unit 13.
Y=(A−D)/(1+(X/C){circumflex over ( )}B)+D (1)
Next, in step s3, prior to initiation of therapy, two condition parameters are selected in advance from cell viability (Y), intracellular PpIX accumulation (X), and light irradiation energy density (P) through the data input unit 11, and the processor 10 determines the remaining condition parameter using the regression curve stored in the data storage unit 12. The two condition parameters selected in advance and the determined condition parameter can be stored in the data storage unit 12 and displayed on the data output unit 13. The light irradiation may be performed not only once but also divided into twice or more. In this case, the sum of the energy densities of the respective irradiation times is equal to the light irradiation energy density (P).
For example, 1) in a case the cell viability (Y) and the intracellular PpIX accumulation (X) are selected in advance, the light irradiation energy density (P) can be determined using the regression curve. The determined light irradiation energy density (P) is supplied to the light intensity control unit 21 to control both the amount of irradiation and the number of irradiation times of light emitted from the light source 20.
In addition, 2) in a case the cell viability (Y) and the light irradiation energy density (P) are selected in advance, the intracellular PpIX accumulation (X) can be determined using the regression curve. In this case, a photodynamic therapy composition containing 5-aminolevulinic acids having a dose corresponding to the intracellular PpIX accumulation (X) thus determined can be produced.
3) In a case the intracellular PpIX accumulation (X) and the light irradiation energy density (P) are selected in advance, the cell viability (Y) can be determined using the regression curve.
When a regression curve is used, such a mathematical expression may be used, but a lookup table obtained by converting correlation between the condition parameters P, X, and Y into a database in a digital format may also be used.
Amounts of protoporphyrin IX (PpIX) accumulated in cells by 5-ALA loading (0, 0.0625, 0.125, 0.25, and 0.5 mmol/L) were measured using the fluorescence detection high-performance liquid chromatography method using four cell lines (ATN-1, TL-Om1, HuT102 and MT-1) derived from human adult T-cell leukemia/lymphoma (ATL) and one kind of HTLV-1 transformed cell line (C8166). Furthermore, as a cell killing assay by PDT, all cells were irradiated with light rays having a central wavelength of 630 nm (10, 30, and 100 J/cm2), and cell viability (%) were calculated with Cell Counting Kit-8 for quantitation of viable cell number. For the results of all cell lines, the cell viabilities were plotted on a vertical axis and the amounts of intracellular PpIX accumulation were plotted on a horizontal axis for each light irradiation energy density, and regression analysis was performed with statistical analysis software SAS software Release 9.3 (
For Jurkat cells derived from human T-cell leukemia which is a disease classification different from that of the human adult T-cell leukemia/lymphoma clinically, amounts of protoporphyrin IX accumulated in the cells by 5-ALA loading (0, 0.0625, 0.125, 0.25, 0.5 and 1 mmol/L) were measured using the fluorescence detection high-performance liquid chromatography method, and then light irradiation (30 J/cm2) with a central wavelength of 630 nm was further performed as the cell killing assay by PDT, and then cell viabilities (%) using the cell counting kit (Cell Counting Kit-8) were calculated. As a result, the cell viabilities were located on the regression curve described in
After a cancer patient takes 5-ALAs, PpIX accumulation (X) accumulated in patient cancer cells is measured, and then the intracellular PpIX accumulation and a therapeutic target value of a killing effect (corresponding to cell viability (Y)) is input to a photodynamic therapy apparatus. The photodynamic therapy apparatus determines light irradiation energy density (P) corresponding to the therapeutic target value by referring to a regression curve programmed in advance from the input values or a lookup table having a stepwise range derived from the regression curve, and then performs therapy. At this time, the intracellular PpIX accumulation, the therapeutic target value of the killing effect, and the light irradiation energy density may be continuous values or stepwise values.
The intracellular PpIX accumulation (X) to be treated is measured, and then this value is input to the photodynamic therapy apparatus. By referring to the regression curve programmed in advance from the input intracellular PpIX accumulation or the lookup table having a stepwise range derived from the regression curve, cell viability (Y) can be calculated for any light irradiation energy densities (P), and then therapeutic effect prediction or therapy is performed. The intracellular PpIX accumulation, the light irradiation energy density, and the cell viability may be continuous values or stepwise values.
After one or more photodynamic therapies are administered to the patient using condition parameters (for example, light irradiation energy density) determined using the regression curve or the lookup table as described above, the cell viability of the patient is measured. From the light irradiation energy density and the cell viability at that time, the intracellular PpIX accumulation (X) or a range of the accumulation in the patient cancer cells is calculated based on the regression curve programmed in the photodynamic therapy apparatus.
Furthermore, from the PpIX accumulation (X) calculated after the therapy is performed as described above, a medical worker can reset the light irradiation energy density (P) and the 5-ALA dose based on the regression curve programmed in the photodynamic therapy apparatus in order to obtain the target therapeutic effect when performing the next photodynamic therapy.
The present invention is industrially very useful in that the photodynamic therapy can be optimized.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/JP2019/006078 | 2/19/2019 | WO |
